Revalving to treat transcatheter valve failure
- PMID: 37660718
- DOI: 10.1016/S0140-6736(23)01735-X
Revalving to treat transcatheter valve failure
Conflict of interest statement
NMVM has received (all unrelated to the topic discussed here) research grant support from Abbott Vascular, Boston Scientific, Medtronic, Edwards Lifesciences, and Daiichi Sankyo; consulting fees from Anteris, JenaValve, Abbott Vascular, Boston Scientific, Medtronic, Daiichi Sankyo, Amgen, Siemens, Pie Medical, CSI, and Shockwave; and speaker's fees from Anteris, Daiichi Sankyo, Medtronic, Abbot Vascular, Boston Scientific, and Amgen. SV declares no competing interests.
Comment on
-
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement.N Engl J Med. 2020 Jan 29;382(9):799-809. doi: 10.1056/NEJMoa1910555. Print 2020 Feb 27. N Engl J Med. 2020. PMID: 31995682 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources